Evidence map›Paper›PMID 41606682›Full record

ArticleGenome biology2026

Genetic associations of circulating plasma proteins with cardiometabolic diseases.

Ruixin Zhou, Jun Qiao, Xiuzhen Zhang, Xiaofei Yang, Wanzi Hong, Liuyang Cai, Pengwei Zhang, Siim Pauklin, Yining Yang, Zhaoyan Xu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruixin Zhou *Department of Pharmacology, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology; Department of Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518055, Guangdong, China.
Jun Qiao *Department of Pharmacology, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology; Department of Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518055, Guangdong, China.
Xiuzhen Zhang *Department of Endocrinology, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518020, Guangdong, China.
Xiaofei YangTranslational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518020, Guangdong, China.
Wanzi HongDepartment of Cardiology, the First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, 528000, Guangdong, China.
Liuyang CaiDepartment of Pharmacology, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology; Department of Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518055, Guangdong, China.
Pengwei ZhangDepartment of Pharmacology, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology; Department of Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518055, Guangdong, China.
Siim PauklinBotnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Headington, Oxford, UK. pauklin@ndorms.ox.ac.uk.
Yining YangDepartment of Cardiology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, 830000, Xinjiang Uygur Autonomous Region, China. yangyn5126@xjrmyy.com.
Zhaoyan XuDepartment of Cardiology, the First People's Hospital of Foshan (Foshan Hospital Affiliated to Southern University of Science and Technology), School of Medicine, Southern University of Science and Technology, Foshan, 528000, Guangdong, China. xuzhaoyanccu@gmail.com.
Yuliang FengDepartment of Pharmacology, SUSTech Homeostatic Medicine Institute, School of Medicine, Southern University of Science and Technology; Department of Geriatrics, Shenzhen People's Hospital (the First Affiliated Hospital of Southern University of Science and Technology), Shenzhen, 518055, Guangdong, China. fengyl@sustech.edu.cn.

Funding

BEIJING medical award foundation YXJL-2025-0106-0190Cancer Research UK C59392/A25064Guangdong Basic and Applied Basic Research Foundation for Distinguished Young Scholars 2024B1515020047National Natural Science Foundation of China 82260073National Natural Science Foundation of China 82470452National Natural Science Foundation of China Young Student Basic Research Program (PhD candidate) 325B2015National Science and Technology Major Project 2023ZD0505902Natural Science Foundation of China Excellent Young Scientists Fund (Overseas) K241141101Natural Science Foundation of Xinjiang Uygur Autonomous Region 2024D01D15Shenzhen Basic Research General Projects of Shenzhen Science and Technology Innovation Commission JCYJ20230807093514029Shenzhen Medical Research Funds B2502036Shenzhen Science and Technology Innovation Program GJHZ20240218111401002Tianshan Talent Cultivation Program Project of Xinjiang Uygur Autonomous Region 2022TSYCLJ0028
6 · The paper itself

Abstract

backgroundCardiovascular disease is the leading cause of death worldwide, and its risk is closely linked to metabolic abnormalities. Through summary-data-based mendelian randomization and colocalization analysis, we investigate the causal relationships between plasma proteins, six cardiovascular diseases (atrial fibrillation, coronary artery disease, heart failure, venous thromboembolism, peripheral artery disease and stroke), and 19 metabolic traits (including anthropometric phenotypes, blood pressure, glycemic phenotypes, inflammatory phenotypes, kidney-related phenotypes, lipidemic phenotypes, and liver-related phenotypes).

resultsWe identify 49 proteins genetically associated with cardiovascular diseases, validated across two proteomic platforms. Among them, 35 are also associated with one or more metabolic phenotypes, with six showing evidence of colocalization. These six candidate proteins are classified into three categories based on drug development status, with PCSK9 already successful in therapies for cardiovascular diseases and hypercholesterolemia. DUSP13B, LRIG1, APOH, INHBC, and GUSB also demonstrate high therapeutic potential. Further phenome-wide MR analysis indicates that INHBC, APOH and DUSP13B represent promising therapeutic targets for cardiovascular diseases characterized by metabolic disorders.

conclusionsOverall, this study revealed causal plasma proteins underlying the onset of cardiovascular diseases and metabolic abnormalities, advancing the understanding of disease mechanisms and facilitating drug discovery.

Indexed as

Blood ProteinsCardiovascular DiseasesMetabolic DiseasesGenetic Predisposition to DiseaseHumansMendelian Randomization AnalysisPhenotypeBlood ProteinsCardiovascular diseasesDrug targetMendelian randomizationMetabolic phenotypesProteome

Identifiers

PMID41606682
PMCPMC12924215

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.